Theriva Biologics, Inc. (TOVX) stock surged over 30% after the company announced it was chosen as a finalist for Merck KGaA’s EMEA Advance Biotech Grant. This prestigious grant provides financial support and guidance to promising biotech companies. Theriva’s General Director of EU Subsidiary, Manel Cascalló, will present their innovative cancer treatment, VCN-01, at the BIO Europe 2024 conference in Stockholm, Sweden. Investors are optimistic about Theriva’s potential and the implications this grant could have for the company’s future.